Review

Psychotherapies for borderline personality disorder: a focused systematic review and meta-analysis

Jutta M. Stoffers-Winterling*, Ole Jakob Storebø*, Mickey T. Kongerslev, Erlend Faltinsen, Adan Todorovac, Mie Sedoc Jørgensen, Christian P. Sales, Henriette Edemann Callesen, Johanne Pereira Ribeiro, Birgit A. Völmm, Klaus Lieb* and Erik Simonsen*

Background
A recently updated Cochrane review supports the efficacy of psychotherapy for borderline personality disorder (BPD).

Aims
To evaluate the effects of standalone and add-on psychotherapeutic treatments more concisely.

Method
We applied the same methods as the 2020 Cochrane review, but focused on adult samples and comparisons of active treatments and unspcific control conditions. Standalone treatments (i.e. necessarily including individual psychotherapy as either the sole or one of several treatment components) and add-on interventions (i.e. complementing any ongoing individual BPD treatment) were analysed separately. Primary outcomes were BPD severity, self-harm, suicide-related outcomes and psychosocial functioning. Secondary outcomes were remaining BPD diagnostic criteria, depression and attrition.

Results
Thirty-one randomised controlled trials totalling 1870 participants were identified. Among standalone treatments, statistically significant effects of low overall certainty were observed for dialectical behaviour therapy (self-harm: standardised mean difference (SMD) −0.54, P = 0.006; psychosocial functioning: SMD −0.51, P = 0.01) and mentalisation-based treatment (self-harm: risk ratio 0.51, P < 0.0007; suicide-related outcomes: risk ratio 0.10, P < 0.0001). For adjunctive interventions, moderate-quality evidence of beneficial effects was observed for DBT skills training (BPD severity: SMD −0.66, P = 0.002; psychosocial functioning: SMD −0.45, P = 0.002), and statistically significant low-certainty evidence was observed for the emotion regulation group (BPD severity: mean difference −8.49, P < 0.00001), manual-assisted cognitive therapy (self-harm: mean difference −3.03, P = 0.03; suicide-related outcomes: SMD −0.96, P = 0.006) and the systems training for emotional predictability and problem-solving (BPD severity: SMD −0.48, P = 0.002).

Conclusions
There is reasonable evidence to conclude that psychotherapeutic interventions are helpful for individuals with BPD. Replication studies are needed to enhance the certainty of findings.

Keywords
Borderline personality disorder; psychotherapy; systematic review; meta-analysis; treatment.

Copyright and usage
© The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

The role of psychotherapy in borderline personality disorder treatment
Although borderline personality disorder (BPD) has been regarded as mostly unresponsive to psychotherapy since its introduction into the DSM in 1980,1 the development of disorder-specific treatment approaches has led to therapeutic optimism. To date, psychotherapy is recommended as the primary treatment for BPD,2,3 and drug treatment only plays an adjunctive role.6 Since pharmacotherapy is not associated with convincing, sustainable effects on BPD pathology,7 therapeutic research now primarily focuses on psychotherapy.

Current evidence
In 2020, the Cochrane review on psychological therapies for people with BPD was updated.8 Since the publication of its previous version in 2012,8 the number of eligible studies had more than doubled, and the 2020 review included 75 randomised controlled trials (RCTs). The 2020 Cochrane review supports the primary role of psychotherapies in BPD treatment. Specifically, a clinically relevant reduction in BPD symptom severity by disorder-specific psychotherapies of any kind was observed, compared with treatment as usual (TAU) (standardised mean difference (SMD) −0.52, 95% CI −0.70 to −0.33, n = 22 RCTs, n = 1244 participants), and there was also evidence of superiority in terms of self-harm (SMD −0.32, 95% CI −0.49 to −0.14, n = 13 RCTs, n = 616 participants), suicide-related outcomes (SMD −0.34, 95% CI −0.57 to −0.11, n = 13 RCTs, n = 666 participants) and psychosocial functioning (SMD 0.45, 95% CI 0.22–0.68, n = 22 RCTs, n = 1314 participants).8

Although a broad variety of treatments have been investigated in RCTs, a large proportion of treatments have only been evaluated in a single trial. If the evidence is restricted to a single study, it must be interpreted cautiously, especially in this field of research: The observation size per study is usually very small (only five out of the 75 primary studies of the 2020 Cochrane review included 100 or more participants). Additionally, the treatment developers themselves are usually the first to evaluate their respective therapies, so a risk of affiliation bias is present in the majority of cases where there is only one study available. Overall, the certainty of the evidence is usually very low if only a single study is available. Therefore, this paper concentrates on any psychotherapeutic treatment with corresponding evidence from at least two RCTs. Furthermore, this paper analyses psychological therapies that were delivered as the primary treatment separately from those

---

* J.M.S.-W. and O.J.S. are joint first authors. K.L. and E.S. are joint last authors.
interventions that supplemented already ongoing individual psychotherapies. This is done to reduce clinical heterogeneity among primary studies and enhance the applicability of findings to individual clinical situations of people affected by BPD.

Method

This review was conducted in accordance with the Cochrane guidelines. Its protocol was published open-access in the Cochrane Database of Systematic Reviews (CDSR) in February 2018, and also on the PROSPERO website (registration number PROSPERO 2018 CRD42018091043). Data extraction was started upon notice of acceptance of the protocol to be published in the CDSR on 22 January 2018. Although the pre-registered methods of the 2020 full review are maintained, this subsidiary paper focuses on comparisons of active treatments and unspecific controls, updates the search and applies a more nuanced perspective, as any adaptations of a standard treatment are analysed individually (e.g. standard dialectical behaviour therapy (DBT) and DBT skills training (DBT-ST) are subject to separate analyses). Interventions are classified as standalone alone or add-on treatments: standalone treatments are defined as necessarily including individual psychotherapy, be it as the sole treatment component or in combination with other treatment elements, or modules. For example, standard mentalisation-based treatment (MBT) or DBT, which include both individual and group interventions, would be classified as standalone treatments, as would any other individual psychotherapy without complementing group. In contrast, add-on interventions are defined as interventions that complement any ongoing individual BPD treatment.

Moreover, we concentrate on adult samples in this paper, adolescent samples being subject to other systematic reviews. The review methods had been declared in the Cochrane protocol. The same literature search methods are applied as in the 2020 Cochrane review, where comprehensive searches were done in 21 databases and trial registries up to 19 March 2019. For this publication, the complete searches were updated on 6 October 2020 (see Supplementary Material available at https://doi.org/10.1192/bjp.2021.204 for search strings). Additionally, we emailed researchers working in the field to ask for unpublished data. We also checked abstracts of key conferences for BPD and asked for any relevant unpublished data. On 9 February 2021, we additionally updated the searches in PubMed and the Cochrane Central Register of Controlled Trials, and also traced up any references included as ongoing in the 2020 Cochrane review, for full publications. There were no language or publication format restrictions.

As for the 2020 Cochrane review, at least 70% of the study participants had to have a formal diagnosis of BPD according to the DSM-III-10,11 or emotionally unstable personality disorder, borderline type, according to the ICD-10.12 We included trials with BPD subsamples of <70% BPD if we had obtained separate data for them from the study authors upon our request. We included studies with or without co-occurring psychiatric conditions. We excluded trials of participants with mental impairment, organic brain disorder, dementia or other severe neurologic or neurodevelopmental diseases.

We included RCTs comparing an active treatment with any kind of unspecific control treatment (i.e. excluding any defined psychotherapeutic BPD treatment), be it TAU, waiting list, case management, standard care or similar. In contrast to the 2020 Cochrane review, we pooled comparisons to any of these controls in the same analyses in this study, since post hoc subgroup analyses of the 2020 Cochrane review revealed no differences between comparisons with different kinds of unspecific controls, supporting the pooling of such data within the same analysis.

Global BPD symptom severity, self-harm, suicide-related outcomes (covering suicidal ideation and suicidal behaviour) and psychosocial functioning were the primary outcomes. Secondary outcomes included single BPD symptoms according to criteria from the DSM-III13,14 to DSM-5, depression and attrition. If trials reported two or more measures for a particular outcome, we selected the one used most often among all included trials, to minimise heterogeneity of outcomes in form and content. If a trial reported data of two assessment instruments that were equally frequently used, two review authors discussed the issue and chose the one most appropriate for the assessment of people affected by BPD. We did not calculate effect estimates for the outcome of attrition from studies including no treatment or waiting list controls, since participants allocated to these conditions did not receive any treatment that they could have dropped out from (see Supplementary Material, PICOS table).

Review authors worked in pairs and independently screened titles and abstracts of all records retrieved by the searches. We reported the reason for exclusion for all relevant studies. The methodological quality of the studies was independently assessed by two reviewers regarding the risk of bias, using the Cochrane Collaboration risk of bias tool.20 We developed data extraction forms to facilitate the standardisation of data extraction. Working in pairs, all review authors extracted data independently, using the data collection form to ensure accuracy. As for study selection, we resolved disagreements by discussion or by involving a third reviewer. Effect sizes were calculated with RevMan 5, 64 bit version for windows.

For continuous outcomes, we compared the mean difference and presented this with 95% confidence intervals to combine the same outcome measures from trials. We calculated the SMDs on basis of post-treatment results in the meta-analysis if there were two or more different instruments used to measure the same construct. If trials did not report mean values and s.d. but reported other values like t-tests and F-values, we tried to transform these into s.d. values. The inverse-variance meta-analysis method was used for pooling the data. For dichotomous data, the risk ratio was calculated. We used the random-effects model for our meta-analyses, as we expected clinical heterogeneity to be present in most analyses. We calculated effect sizes on basis of intention-to-treat data, if possible. We investigated statistical heterogeneity by both visual inspection of the graphs and the I² statistic.22 We considered I² values 0–40% as indicating low heterogeneity, 30–60% as indicating possibly moderate heterogeneity, 50–90% as indicating possibly substantial heterogeneity and 75–100% as indicating considerable heterogeneity.23 The overlap of intervals allows for individual factors when interpreting the importance of inconsistency of study estimates included in the same analysis, e.g. the magnitude and direction of effect, and the strength of evidence for heterogeneity.

We applied the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tool to assess the quality, or certainty, of the overall body of evidence. All ratings were discussed by the two primary authors (J.M.S.-W. and O.J.S.). The following five domains were taken into account to rate the certainty of the findings for any primary outcome: risk of bias in primary studies (based on Cochrane Risk of Bias tool20 ratings), inconsistency (i.e. high heterogeneity) of primary study findings, indirectness of the evidence, imprecision (finding based on a single trial, wide confidence intervals) and publication bias (i.e. bias owing to the non-publication of studies with negative undesired results). We drew funnel plots for the primary and secondary outcomes with the highest numbers of available study effect estimates, to investigate the possibility of publication bias.
Ethical considerations
For preparing this systematic reviewer and meta-analysis, no deeply personal, sensitive or confidential information was collected from individual participants. Any data was anonymised and drawn from publicly accessible documents. Therefore, no formal ethics approval was sought.

Results
Of the 75 RCTs included in the 2020 Cochrane review, 30 were eligible for inclusion in this focused review of comparisons with unspecific control interventions in adult samples (Fig. 1). The updated searches done for the present review retrieved 54 records, two of which referred to two unique new eligible RCTs. In total, 32 trials were available for qualitative analysis. We excluded one RCT from the quantitative analyses because of substantial concerns about the study validity (see next section). Finally, 31 RCTs, including 1870 participants, were included in the quantitative analyses (Table 1).

Description of studies and risk of bias
Fifteen RCTs were conducted in Europe, 14 in North America, two in Iran and one in New Zealand. The publication period spanned almost three decades (1991–2020), but only three RCTs were published before 2000. Twelve samples included women only, whereas one concentrated on men only. The remaining studies consisted predominantly of females (58–96%). The sample mean age ranged from 19.3 to 45.7 years. In two RCTs, distinct co-occurring psychiatric disorders were required for study inclusion, i.e. comorbid post-traumatic stress disorder (PTSD), and in two trials, participants were referred to usual treatment for BPD in that specific setting. Forty-eight of the 32 included trials investigated standalone treatments: DBT (n = 10), MBT (n = 4), interpersonal therapy (n = 2), cognitive–behavioural therapy (n = 2), dynamic deconstructive psychotherapy (DDP; n = 2). Twenty out of the 32 included trials investigated stand-alone treatments: DBT (n = 10), MBT (n = 4), interpersonal therapy adapted for BPD (IPT-BPD; n = 2), cognitive–behavioural therapy (CBT; n = 2) and dynamic deconstructive psychotherapy (DDP; n = 2).

DBT is based on CBT and, as a multi-modal treatment, combines individual psychotherapy, group skills training, regular therapists team consultations and crisis telephone coaching if needed. MBT also includes individual and group sessions. It is a psychodynamic therapy that draws from attachment and cognitive theory, and aims to enhance the impaired capacity to identify and understand mental states in oneself and others usually found in individuals with BPD. IPT-BPD is an adaption of IPT that had originally been developed for the treatment of major depression. BPD is conceptualised as a chronic mood disorder, and the IPT-BPD adaptation includes a longer treatment duration, more flexibility in treatment settings and treatment intensity, and more focus on the therapeutic relationship. Recently, it has been suggested to complement IPT-BPD with a family intervention aiming to educate significant others about BPD. CBT includes psychodynamic therapy and focuses on restructuring maladaptive core beliefs and patterns of behaviour, and aims to develop new, more adaptive beliefs about the self and others, and more adaptive strategies of behaviour. DDP is a psychodynamic treatment with a strong experiential component that has been developed to specifically meet the needs of individuals with BPD and co-occurring substance use disorder or antisocial personality disorder. It aims to activate impaired neurocognitive functions (e.g. disrupted linkages among affective experiential capacities, memory and verbal/symbolic attribution) by verbalising and elaborating effects and interpersonal experiences. Twelve more studies focused on psychotherapeutic add-on interventions that are intended to complement ongoing individual psychotherapies and are usually delivered in a group format: DBT-ST (n = 2), emotion regulation group (ERG; n = 2), manual-assisted cognitive therapy (MAC; n = 2), psychoeducation (n = 2) and system training for emotional predictability and problem solving (STEPPS; n = 2; see Table 1). The DBT-ST group is part of standard DBT and usually complements DBT individual treatment by introducing and training mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness skills.

Several studies, however, have tested the effects of DBT-ST alone. ERG is a group intervention combining elements of DBT, classic CBT, acceptance- and commitment therapy, and emotion-focused psychotherapy to target emotion dysregulation, and emotional avoidance specifically, among self-harming women. MACT is a brief, six-session intervention aimed at helping individuals understand their self-harming behaviour better, and to reduce distress by enhancing problem-solving skills. This treatment is designed to comply with a self-help manual that is used by treatment-seeking individuals in their preparation for each session. Psychoeducation programmes intend to provide the latest information about BPD epidemiology, phenomenology and treatment options to newly diagnosed individuals with BPD, either in the format of an in-person presentation using slides, or a booklet-type web-based presentation.

Effects of interventions: standalone psychotherapies
The highest number of individual RCTs was available for standard DBT (n = 10 studies), followed by MBT (n = 4...
For each of the remaining standalone treatments under test, two RCTs were identified (CBT, DDP, IPT-BPD). All effect estimates are displayed in Table 2, along with the number of comparisons, participants, the 95% confidence intervals, P-values and I² scores that indicate the percentage of the variability in effect estimates resulting from heterogeneity rather than sampling error (or chance) alone.

For DBT, statistically significant moderate-to-large effects were observed in the primary outcomes of self-harm (SMD \(-0.54\), 95% CI \(-0.92 \) to \(-0.16\), \(n=3\) studies, \(n=110\) participants, \(I^2 = 0\)) and psychosocial functioning (SMD \(-0.51\), 95% CI \(-0.90\) to \(-0.11\), \(n=3\) studies, \(n=115\) participants). Similarly, there was also a statistically significant effect on the secondary outcome of anger (SMD \(-0.83\), 95% CI \(-1.43\) to \(-0.22\), \(n=2\) studies, \(n=46\) participants). Statistical heterogeneity was marginal for all of these effect estimates (0–5%; see Table 2).

MBT was assessed in four studies. The risk of engaging in self-harm (risk ratio 0.51, 95% CI 0.34–0.75, \(n=2\) studies, \(n=172\) participants) or suicidal behaviour (risk ratio 0.10, 95% CI 0.03–0.32, \(n=2\) studies, \(n=172\) participants) was found to be significantly lower in the MBT-treated groups (statistical heterogeneity 0% for both estimates, see Table 2). There were no statistically significant effects for any of the secondary outcomes, but two effect estimates (interpersonal problems, depression) were just beyond the boundaries of significance (\(P=0.06\) and \(P=0.07\)). However, statistical heterogeneity among the four reporting RCTs was substantial for both of these outcomes.

All remaining standalone treatments were subject to two RCTs each. For CBT, depression was the only outcome reported by both corresponding RCTs, which resulted in a statistically non-significant effect and substantial heterogeneity. A statistically significant effect on BPD severity was found by the smaller of these two studies, in terms of 3.08 fewer positive BPD items on the Structured Clinical Interview for DSM-IV71 (95% CI \(-4.99\) to \(-1.17\), \(n=1\) study, \(n=26\) participants) at the end of treatment. The larger study did not find a statistically significant difference in terms of the proportions of participants still meeting diagnostic BPD criteria after treatment (see Table 2).

For DDP, two RCTs were available. Their pooled findings resulted in a statistically significant effect estimate of \(-9.49\) points.
### Table 1 Characteristics of included studies

| Study                                    | Country     | 2012 review | 2020 review | Update search | Sample size (n) | Gender (% female) | Age (mean, years) | Defined comorbiditiesa | Observation period (weeks/months) | Control | Setting       |
|------------------------------------------|-------------|-------------|-------------|---------------|----------------|------------------|-------------------|------------------------|-----------------------------------|---------|---------------|
| Cognitive-behavioral therapy             | Davidson 200654 | UK          | X           | X             | 106            | 84               | 31.9              | –                      | 12 m TAU                         | Out-patient |               |
|                                          | Kredlow 201735 | USA         | X           |               | 27             | 96               | 45.7              | PTSD                  | 3–4 m TAU                         | Out-patient |               |
| Dialectical Behaviour Therapy (DBT)      | Bianchini 201938 | Italy       | X           | X             | 21             | 0                | 41.79             | –                      | 12 months TAU                    | In-patient |               |
|                                          | Carter 201037 | New Zealand | X           | X             | 73             | 100              | 25                | –                      | 6 months TAU                    | Out-patient |               |
|                                          | Feigenbaum 201239 | USA         | X           | X             | 42             | 73               | 31.0              | –                      | 6 months TAU                    | Out-patient |               |
|                                          | Koors 200138 | USA         | X           | X             | 28             | 100              | 35                | –                      | 6 months TAU                    | Out-patient |               |
|                                          | Linehan 199139 | USA         | X           | X             | 61             | 100              | Not specified     | –                      | 6 months TAU                    | Out-patient |               |
|                                          | Linehan 199440 | USA         | X           | X             | 26             | 100              | 26.7              | –                      | 12 months TAU                    | Out-patient |               |
|                                          | Linehan 200541 | USA         | X           | X             | 101            | 100              | 29.3              | –                      | 12 months E-TAU                    | Out-patient |               |
|                                          | Priebel 201242 | UK          | X           | X             | 70             | 87.5             | 32.2              | –                      | 12 months TAU                    | Out-patient |               |
|                                          | Stanley 201743 | USA         | X           | X             | 75             | 77.3             | 30.2              | –                      | 12 months Supportive treatment | Out-patient |               |
|                                          | van den Bosch 200544 | The Netherlands | X           | X             | 58             | 100              | 34.9              | –                      | 12 months TAU                    | Out-patient |               |
| DBT skills training                      | Kramer 201645 | Switzerland | X           | X             | 41             | 87.8             | 34.4              | –                      | 12 months TAU                    | Out-patient |               |
|                                          | McMain 201746 | Canada      | X           | X             | 84             | 78.6             | 29.7              | –                      | 20 weeks Waiting list            | Out-patient |               |
|                                          | Mohammadi-Zadeh 201747 | Iran          | X           | X             | 36             | 100              | Not specified     | –                      | 16 weeks No treatment provided   | In-patient |               |
|                                          | Soler 200948 | Spain       | X           | X             | 59             | 81.3             | 29.2              | –                      | 3 months Supportive treatment    | Out-patient |               |
| Dynamic Deconstructive Psychotherapy (DDP) | Gregory 200849 | USA         | X           | X             | 30             | 80               | 28.7              | Active alcohol misuse or dependence | 12 months TAU                    | Out-patient |               |
|                                          | Majdara 201950 | Iran        | X           | X             | 30             | 60               | 27.3              | –                      | 12 months Supportive treatment   | Out-patient |               |
| Emotion Regulation Group (ERG)           | Gratzi 200651 | USA         | X           | X             | 25             | 100              | 33.3              | –                      | 14 weeks TAU                    | Out-patient |               |
|                                          | Gratzi 201452 | USA         | X           | X             | 61             | 100              | 33.2              | –                      | 14 weeks TAU                    | Out-patient |               |
| Interpersonal Psychotherapy adapted for borderline personality disorder (IPT-BPD) | Bellino 201053 | Italy       | X           | X             | 55             | 67.3             | 26.0              | –                      | 32 weeks Clinical management     | Out-patient |               |
|                                          | Majdara 201954 | Iran        | X           | X             | 36             | 100              | Not specified     | –                      | 10 months Clinical management    | Out-patient |               |
| Manual-Assisted Cognitive Therapy (MACCT) | Weinberg 200655 | USA         | X           | X             | 20             | n.s.             | 18–45             | –                      | 6 weeks TAU                     | Out-patient |               |
| Mentalisation-Based Treatment (MBT)      | Bateman 199956 | UK          | X           | X             | 38             | 57.9             | 31.8              | –                      | 18 months TAU                    | Out-patient |               |
|                                          | Bateman 200957 | UK          | X           | X             | 138            | 79.9             | 31.3              | –                      | 18 months TAU                    | Out-patient | Day hospital |
|                                          | Jorgensen 201358 | Denmark  | X           | X             | 111            | 95.5             | 29.2              | –                      | 12 months Supportive treatment   | Out-patient |               |
|                                          | Laursen 201859 | The Netherlands   | X           | X             | 95             | 79               | Not specified     | –                      | 18 months E-TAU                    | Out-patient | Day hospital |
| Psychoeducation                          | Zanarini 200860 | USA         | X           | X             | 50             | 100              | 19.3              | –                      | 12 weeks Waiting list            | Out-patient |               |
|                                          | Zanarini 201861 | USA         | X           | X             | 80             | 100              | 21.4              | –                      | 12 weeks No treatment provided   | Out-patient |               |
| Systems Training for Emotional Predictability and Problem Solving (STEPPS) | Bijlsma 201062 | The Netherlands | X           | X             | 79             | 86.1             | 32.4              | –                      | 4.5 months TAU                    | Out-patient |               |
|                                          | Bijlsma 200863 | USA         | X           | X             | 124            | 83.1             | 31.5              | –                      | 20 weeks TAU                     | Out-patient |               |

TAU, treatment as usual; PTSD, post-traumatic stress disorders; E-TAU, treatment as usual by experts.

a. As required for inclusion in primary study.
b. Borderline personality disorder subsample data.
c. Forensic.
d. Not included in quantitative analyses.
on the 15-point Borderline Evaluation of Severity Over Time (BEST) questionnaire (95% CI −18.04 to −9.4, n = 2 studies, n = 55 participants). There was also a large pooled, statistically significant effect estimate for the outcome of depression (SMD −0.87, 95% CI −1.64 to −0.10, n = 2 studies n = 56 participants). Statistical heterogeneity was moderate (depression: I² = 45%) to considerable (BPD severity: I² = 67%). Additionally, one of the studies found a statistically significant effect for the outcome of psychosocial functioning in terms of more days paid for work during the past 30 days (mean difference −16.60, 95% CI −22.61 to −10.59; see Table 2).

Although we observed no statistically significant effects of IPT-BPD for any primary outcome, there were several for secondary outcomes, all of which were assessed by the Borderline Personality Disorder Severity Index-IV (BPDSI-IV). There were statistically significant findings from both corresponding studies for the outcome of impulsivity (mean difference −1.69, 95% CI −3.05 to −0.33, n = 2 trials, n = 80 participants) and interpersonal problems (mean difference −1.74, 95% CI −3.01 to −0.47, n = 2 trials, n = 80 participants). Both were associated with considerable statistical heterogeneity (I² = 84% and I² = 72%, respectively). Another statistically significant effect was observed for the outcome of affective instability in one of the studies (mean difference −1.02, 95% CI −1.66 to −0.38, n = 1 trial, n = 44 participants).

Notably, we did not observe a significant effect on outcomes of the so-called cognitive cluster of BPD symptoms, which includes identity disturbance and dissociation/stress-related paranoia, for any of the standalone treatments. There were also no statistically significant attrition rates in experimental and control treatments.

**Effects of interventions: add-on/group psychotherapies**

Twelve RCTs evaluated the effects of five different add-on interventions that are intended to supplement ongoing treatments like individual psychotherapy, or drug treatment. DBT-ST that is usually delivered as a component of standard DBT was subject to four RCTs. Two trials each investigated ERG, MACT, psychoeducation and STEPPS.

For DBT-ST alone, statistically significant moderate effects were observed for the primary outcomes of BPD severity (SMD −0.66, 95% CI −1.08 to −0.25, n = 3 studies, n = 184 participants) and psychosocial functioning (SMD −0.45, 95% CI −0.75 to −0.16, n = 3 studies, n = 184 participants). Heterogeneity was moderate (47%) or nonexistent (0%). There were moderate-to-large statistically significant effects from pooled effect estimates for secondary outcomes related to the impulsive symptom cluster (impulsivity: SMD −0.47, 95% CI −0.80 to −0.14, n = 2 studies, n = 143 participants), emotionally dysregulated cluster (anger: SMD −1.01, 95% CI −1.36 to −0.66, n = 2 studies, n = 143 participants; affective instability: SMD −1.04, 95% CI −1.39 to −0.69, n = 2 studies, n = 143 participants) and depression (SMD −0.72, 95% CI −1.14 to −0.29, n = 2 studies, n = 143 participants). Heterogeneity was nonexistent to low (0% in all cases, except for depression, which had an I² of 35%). Another statistically significant effect in terms of a reduction of psychotic symptoms was observed in a single study (mean difference −3.15 points on the Brief Psychiatry Rating Scale, 95% CI −5.57 to −0.73, n = 1 study, n = 59 participants).

ERG showed statistically significant effects for the primary outcome of BPD severity in terms of an 8.49 points reduction on the BEST questionnaire (95% CI −11.51 to −5.46, n = 2 studies, n = 83 participants). As for secondary outcomes, statistically significant effects were found in terms of a 25.51 points reduction on the Difficulties in Emotion Regulation (DERS) questionnaire total score (95% CI −42.53 to −8.48, n = 2 studies, n = 83 participants), impulsivity (mean difference −0.46 points on the DERS impulsivity subscale, 95% CI −0.86 to −0.07, n = 2 studies, n = 83 participants) and depression (mean difference −9.13 points on the Depression and Anxiety Stress Scales” depression subscale, 95% CI −13.25 to −5.01, n = 2 studies, n = 83 participants). Statistical heterogeneity was nonexistent or low for all secondary outcomes, except affective instability (I² = 71%).

There were statistically significant effects of MACT on the primary outcomes of self-harm in terms of a greater reduction of parasuicide frequency (mean difference −3.03 points on the Parasuicide History Interview frequency subscale, 95% CI −5.68 to −0.38, n = 1 study, n = 28 participants), and a large effect on suicide-related outcomes (SMD −0.96, 95% CI −1.62 to −0.29, n = 2 studies, n = 43 participants, I² = 0%). Finally, there was another single study-based, statistically significant effect for depression (mean difference −11.77 points on the Hospital Anxiety and Depression Scale, 95% CI −18.05 to −5.49, n = 1 study, n = 15 participants).

For psychoeducation, no statistically significant effects were observed for any primary outcome, besides the secondary outcome of impulsivity. The pooled effect estimates of the two corresponding trials resulted in a statistically significant reduction of impulsivity in terms of a reduction of −0.46 points on the Zanarini Rating Scale for Borderline Personality Disorder (Zan-BPD, 95% CI −0.86 to −0.07, n = 2 studies, n = 130 participants). There was no statistical heterogeneity present (I² = 0%).

STEPPS was associated with a moderate, statistically significant effect on the primary outcomes of BPD severity (SMD −0.48, 95% CI −0.78 to −0.18, n = 2 studies, n = 176 participants) and psychosocial functioning (mean difference −7.00 points on the Global Health Questionnaire total score, 95% CI −10.00 to −3.99, n = 2 studies, n = 176 participants).
### Table 2  Effects of interventions

| Outcomes                              | N (comparisons) | n (participants) | Effect sizea | 95% CI | P-value | I²  |
|---------------------------------------|-----------------|------------------|--------------|--------|---------|-----|
| **Standalone treatments:**             |                 |                  |              |        |         |     |
| Cognitive-behavioural therapy (CBT)   |                 |                  |              |        |         |     |
| BPD severity                          | 1               | 76               | RR 0.91      | 0.56–1.48 | 0.71 | – |
| BPD severity                          | 1               | 26               | MD −3.08 (SCID-II BPD items) | −4.99 to −1.17 | 0.002 | – |
| Self-harm                             | 1               | 99               | RR 1.17      | 0.86–1.60 | 0.32 | – |
| Suicide-related outcomes              | 1               | 101              | RR 0.78      | 0.47–1.27 | 0.31 | – |
| Psychosocial functioning              | 1               | 99               | MD 0.00 (SFQ) | −1.78 to 1.78 | 1.00 | – |
| Interpersonal problems                | 1               | 99               | MD 5.40 (IIP-SC) | −3.70 to 14.50 | 0.24 | – |
| Dissociation/psychotic symptoms       | 1               | 26               | MD −2.30 (BPRS) | −8.84 to 4.24 | 0.49 | – |
| Depression                            | 2               | 125              | MD −7.65 (BDI-II) | −20.70 to 5.40 | 0.25 | 78% |
| Attrition                             | 1               | 106              | RR 0.48      | 0.09–2.52 | 0.39 | – |
| **Dialectical Behaviour Therapy (DBT)** |                 |                  |              |        |         |     |
| BPD severity                          | 2               | 90               | SMD −0.36    | −0.78 to 0.05 | 0.09 | 0% |
| Self-harm                             | 3               | 110              | SMD −0.54    | −0.92 to −0.16 | 0.006 | 0% |
| Suicide-related outcomes              | 2               | 109              | SMD −0.60    | −1.71 to 0.51 | 0.29 | 78% |
| Psychosocial functioning              | 1               | 41               | MD 0.18 (SASSI – suicide attempts) | −0.03 to 0.39 | 0.09 | – |
| Depression                            | 3               | 115              | SMD −0.51    | −0.90 to −0.11 | 0.01 | 5% |
| Attrition                             | 9               | 207              | RR 1.33      | 0.69–2.54 | 0.39 | 83% |
| **Dynamic Deconstructive Psychotherapy (DDP)** |                 |                  |              |        |         |     |
| BPD severity                          | 2               | 55               | MD −9.49 (BEST) | −18.04 to −0.94 | 0.03 | 67% |
| Self-harm                             | 1               | 24               | MD −0.12 (LPC) | −0.60 to 0.36 | 0.63 | – |
| Psychosocial functioning              | 1               | 24               | MD −16.60 (SPS – days paid for work past 30 days) | −22.61 to −10.59 | <0.00001 | – |
| Dissociation/psychotic symptoms       | 1               | 24               | MD 5.40 (DES) | −9.63 to 20.43 | 0.48 | – |
| Depression                            | 2               | 56               | SMD −0.87    | −1.64 to −0.10 | 0.03 | 45% |
| Attrition                             | 2               | 60               | RR 0.97      | 0.43–2.19 | 0.93 | 0% |
| **Interpersonal Psychotherapy adapted for borderline personality disorder (IPT-BPD)** |                 |                  |              |        |         |     |
| BPD severity                          | 2               | 80               | MD −4.15 (BPDS-I total score) | −12.26 to 3.97 | 0.32 | 86% |
| Self-harm                             | 2               | 80               | SMD 0.28     | −0.28 to 0.85 | 0.33 | 38% |
| Psychosocial functioning              | 2               | 80               | MD −0.47 (CGI-S) | −1.41 to 0.47 | 0.331 | 89% |
| Anger                                 | 1               | 44               | MD 0.01 (BPDS-I – anger) | −0.40 to 0.42 | 0.96 | – |
| Affective instability                 | 1               | 44               | MD −1.02 (BPDS-I–II – affective instability) | −1.66 to −0.38 | 0.002 | – |
| Emptiness                             | 1               | 44               | MD 0.04      | −0.21 to 0.29 | 0.75 | – |
| Impulsivity                           | 2               | 80               | MD −1.69 (BPDS-I–II – impulsivity) | −3.05 to −0.33 | 0.01 | 84% |
| Interpersonal problems                | 2               | 80               | MD −1.74 (BPDS-I–II – interpersonal problems) | −3.01 to −0.47 | 0.007 | 72% |
| Abandonment                           | 1               | 44               | MD 0.01 (BPDS-I – abandonment) | −0.90 to 0.92 | 0.98 | – |
| Identity disturbance                  | 2               | 80               | MD −0.31 (BPDS-I – identity disturbance) | −0.97 to 0.34 | 0.35 | 53% |
| Dissociation/psychotic symptoms       | 1               | 44               | MD 0.23 (BPDS-I–II – paranoid ideation) | −1.06 to 1.52 | 0.73 | – |
| Depression                            | 1               | 44               | MD −0.07 (Ham-D) | −0.97 to 0.83 | 0.88 | – |
| Attrition                             | 2               | 98               | RR 0.52      | 0.19–1.42 | 0.20 | 0% |
| **Mentalisation-Based Treatment (MBT)** |                 |                  |              |        |         |     |
| BPD severity                          | 2               | 161              | SMD −0.17    | −0.49 to 0.14 | 0.28 | 0% |
| Self-harm                             | 2               | 172              | RR 0.51      | 0.34–0.75 | <0.0007 | 0% |
| Suicide-related outcomes              | 2               | 172              | RR 0.10      | 0.03–0.32 | <0.0001 | 0% |
| Psychosocial functioning              | 3               | 239              | MD −0.33 (SAS-SR) | −0.74 to 0.09 | 0.12 | 85% |
| Interpersonal                          | 4               | 333              | SMD −0.75    | −1.53 to 0.02 | 0.06 | 90% |
| Depression                            | 4               | 333              | SMD −0.58    | −1.22 to 0.05 | 0.07 | 86% |
| Attrition                             | 4               | 358              | RR 1.05      | 0.74–1.49 | 0.87 | 0% |

(Continued)
Table 2 (Continued)

| Outcomes | \( N \) (comparisons) | \( n \) (participants) | Effect size* | 95% CI   | P-value | \( I^2 \) |
|----------|------------------------|------------------------|--------------|----------|---------|---------|
| Add-on treatments: DBT skills training | | | | | | |
| BPD severity | 3 | 184 | SMD –0.66 | –1.08 to –0.25 | 0.002 | 47% |
| Suicide-related outcomes | 3 | 143 | SMD –0.20 | –0.53 to 0.13 | 0.24 | 0% |
| Psychosocial functioning | 3 | 184 | SMD –0.45 | –0.75 to –0.16 | 0.002 | 0% |
| Anger | 2 | 143 | SMD –1.01 | –1.36 to –0.66 | <0.00001 | 0% |
| Affective instability | 2 | 143 | SMD –1.04 | –1.39 to –0.69 | <0.00001 | 0% |
| Emptiness | 1 | 59 | MD –0.67 (CGI-BPD – emptiness) | –1.45 to 0.11 | 0.09 | 0% |
| Impulsivity | 2 | 143 | SMD –0.47 | –0.80 to –0.14 | 0.006 | 0% |
| Interpersonal | 2 | 100 | SMD –0.20 | –0.59 to 0.19 | 0.32 | 0% |
| Dissociation/psychotic | 1 | 59 | MD –3.15 (BPRS) | –5.57 to –0.73 | 0.01 | 0% |
| Depression | 2 | 143 | SMD –0.72 | –1.14 to –0.29 | <0.00001 | 35% |
| Attrition | 3 | 101 | RR 0.64 | 0.39–1.04 | 0.07 | 0% |
| Emotion Regulation Group (ERG) | | | | | | |
| BPD severity | 2 | 83 | MD –8.49 (BEST) | –11.51 to –5.46 | <0.00001 | 0% |
| Self-harm | 2 | 83 | MD –1.07 (DSH) | –3.11 to 0.96 | 0.30 | 73% |
| Psychosocial functioning | 1 | 61 | MD –1.76 (DSIS) | –4.89 to 1.37 | 0.27 | 0% |
| Affective instability | 2 | 83 | MD –25.51 (DEFS) | –42.53 to –8.48 | 0.003 | 71% |
| Impulsivity | 2 | 83 | MD –0.46 (DEFS – impulsivity) | –0.86 to 0.07 | 0.02 | 0% |
| Interpersonal problems | 1 | 61 | MD –0.85 (IIP-BPD) | –1.37 to –0.32 | 0.02 | 0% |
| Depression | 2 | 83 | MD –9.13 (DASS – depression) | –13.25 to –5.01 | <0.00001 | 18% |
| Attrition | 2 | 85 | RR 1.41 | 0.43–4.68 | 0.57 | 0% |
| Manual-Assisted Cognitive Treatment (MACT) | | | | | | |
| Self-harm | 1 | 28 | MD –3.03 (PHI-frequency) | –5.68 to –0.38 | 0.03 | 0% |
| Suicide-related outcomes | 2 | 43 | SMD –0.96 | –1.62 to –0.29 | 0.005 | 0% |
| Depression | 1 | 15 | MD –11.77 (HADS) | –18.05 to –5.49 | <0.00002 | 0% |
| Attrition | 1 | 30 | RR 0.20 | 0.01–3.85 | 0.29 | 0% |
| Psychoeducation | | | | | | |
| BPD severity | 1 | 80 | MD –1.33 (Zan-BPD – total) | –3.96 to 1.30 | 0.32 | 0% |
| Psychosocial functioning | 1 | 80 | MD –0.14 (SAS) | –0.58 to 0.30 | 0.52 | 0% |
| Impulsivity | 2 | 130 | MD –0.46 (Zan-BPD – impulsivity) | –0.86 to –0.07 | 0.02 | 0% |
| Interpersonal problems | 2 | 130 | MD –0.34 (Zan-BPD – interpersonal cluster) | –1.08 to 0.39 | 0.36 | 75% |
| Dissociation/psychotic symptoms | 1 | 80 | MD –0.26 (Zan-BPD – cognitive cluster) | –0.98 to 0.46 | 0.48 | 0% |
| Depression | 1 | 80 | MD –6.11 (CUDOS – total) | –12.77 to 0.55 | 0.07 | 0% |
| Systems Training for Emotional Predictability and Problem Solving (STEPSS) | | | | | | |
| BPD severity | 2 | 176 | SMD –0.48 | –0.78 to –0.18 | 0.002 | 0% |
| Self-harm | 1 | 29 | Risk ratio 1.32 | 0.78–2.22 | 0.30 | 0% |
| Psychosocial functioning | 1 | 124 | MD –7.00 (GAS) | –11.43 to –2.57 | 0.002 | 0% |
| Affective instability | 1 | 124 | MD –1.00 (Zan-BPD – affective instability) | –2.11 to 0.11 | 0.06 | 0% |
| Impulsivity | 1 | 124 | MD –0.40 (Zan-BPD – impulsivity) | –1.23 to 0.43 | 0.35 | 0% |
| Interpersonal problems | 2 | 177 | SMD –0.38 | –0.67 to –0.08 | 0.01 | 0% |
| Dissociation/psychotic symptoms | 2 | 124 | MD –1.00 (Zan-BPD – cognitive subscale) | –1.83 to –0.17 | 0.02 | 0% |
| Depression | 1 | 124 | MD –3.80 (BDI) | –9.34 to 1.74 | 0.18 | 0% |
| Attrition | 2 | 203 | RR 1.91 | 1.03–3.39 | 0.02 | 0% |

Bold text indicates statistically significant effects (95% Confidence Interval); BDI, Beck Depression Inventory; BDI-II, Beck Depression Inventory-II; BEST, Borderline Evaluation of Severity overTime; BPDs-IV, Borderline Personality Disorder Severity Index-IV; BPRS, Brief Psychiatric Rating Scale; CGI-BPD, Clinical Global Impression Scale for Borderline Personality Disorder; CGI-S, Clinical Global Impression Scale–Severity subscale; CI, Confidence Interval; CUDOS, Clinically Useful Depression Outcome Scale; DASS, Depression and Anxiety Stress Scale; DDP, Dynamic Deconstructive Psychotherapy; DSM, Difficulties in Emotion Regulation Scale; DSII, Dissociative Experience Scale; DSD, Deliberate Self-Harm Inventory; GAS, Global Assessment Scale; HADS, Hospital Anxiety and Depression Scale; IIP, Hamilton Depression Scale; IIP-BPD, BPD-related composite of the Inventory of Interpersonal Problems; IIP-SC, Inventory of Interpersonal Problems-Short Circumplex; LPC, Lifetime Panic Count; MD, mean difference; PHI, Panasiea Anxiety History Interview; RR, risk ratio; SAS, Social Adjustment Scale; SASS, Suicide Attempt Self Injury Interview; SAS-SS, Social Adjustment Scale–Self-Rating; SDI-IV, Structured Clinical Interview for DSM-IV Axis I Personality Disorders; SDS, Sheehan Disomabili Scale; SFQ, Social Functioning Questionnaire; SMD, standardized mean difference; SPS, Social Provisions Scale; STAI, Start Trait Anger Expression Inventory; WHO-QoL-Bref, World Health Organization Quality of Life-Questionnaire—abbreviated version; Zan-BPD, Zanarini Rating Scale for Borderline Personality Disorder.

* Negative mean differences sec standardised mean differences or Risk Ratios < 1 indicate beneficial effects by the experimental treatment data.

b. Log-transformed data.

Assessment Scale.\(^{60}\) 95% CI –11.43 to –2.57, \( n = 1 \) study, \( n = 124 \) participants). For secondary outcomes, a statistically significant effect in terms of a reduction of interpersonal problems (SMD –0.38, 95% CI –0.67 to –0.08, \( n = 2 \) studies, \( n = 177 \) participants) and cognitive cluster symptoms (mean difference –1.00 points on the Zan-BPD cognitive cluster subscale, 95% CI –1.83 to –0.17, \( n = 1 \) study, \( n = 124 \) participants) was found. There was also a higher proportion of attrition in the STEPPS-treated groups (risk ratio 1.91, 95% CI 1.03–3.39, \( n = 2 \) studies, \( n = 203 \) participants). All pooled effect estimates for STEPPS were free of substantial statistical heterogeneity (\( I^2 = 0\% \) for all comparisons).

Quality of the evidence

The quality of the evidence was rated very low for most outcomes and comparisons, primarily because of imprecision (based on single trials only, wide confidence intervals) and risk of bias in primary studies. Table 3 summarises the findings on primary outcomes along with GRADE ratings of the evidence quality.

The quality, or certainty of the evidence was not rated high for any comparison and outcome. It was considered moderate for DBT-ST (BPD severity, suicide-related outcomes, psychosocial functioning) and low for DBT (BPD severity, self-harm, suicide-related...
outcomes, psychosocial functioning), IPT-BPD (self-harm), MBT (BPD severity, self-harm, suicide-related outcomes), ERG (BPD severity), MACT (self-harm, suicide-related outcomes) and STEPPS (BPD severity). The quality of all remaining comparisons and outcomes was regarded as very low.

To assess the risk of bias from publication bias as well as small-study effects, we drew a funnel plot for the two most prevalent outcomes across all studies, BPD severity and depression (Fig. 3). While the visual inspection of the funnels identified a trend of asymmetry in terms of missing unfavourable results from more imprecise, smaller studies, a small-study effect became evident for both outcomes, as effect estimates of smaller studies clearly differed from those of larger studies. Therefore, a non-reporting bias due to the inavailability of smaller trials with unfavourable outcomes cannot be ruled out. On the other hand, asymmetry might also be caused by the tendency of smaller studies to be associated with exaggerated effects of estimates.
Discussion

This review is based on a comprehensive search and updates and complements the 2020 Cochrane review, with a more nuanced view on individual treatment approaches. By investigating treatment effects of standalone psychotherapies and add-on interventions, we found beneficial effects for both regarding the primary outcomes of BPD severity, psychosocial functioning, self-harm and suicide-related outcomes, and the secondary outcomes of specific BPD diagnostic criteria and depression. However, the quality or certainty of the evidence was rated low or very low in the majority of cases. Among standalone treatments, statistically significant effect estimates as supported by at least low-certainty

![Funnel plots. SMD, standardised mean difference.](https://doi.org/10.1192/bjp.2021.204)
evidence were only found for DBT (self-harm, psychosocial functioning) and MBT (self-harm, suicide-related outcomes). The quality of the evidence for some add-on treatments was good, with moderate-quality evidence of beneficial effects by DBT-ST groups on the primary outcomes of BPD severity and psychosocial functioning.

Although head-to-head comparisons of treatments were not examined in this paper, the results support the conclusion that beneficial effects can be observed by different interventions. More research is needed to foster our understanding of helpful treatment components across distinct treatment methods. In recent years, suggestions have been made regarding individual methods and pointing to the need to accompany and guide individuals with BPD long term, using generalist methods, with the most prominent being general psychiatric management.

Completeness of the evidence

As in the 2020 Cochrane review, the samples included in the primary studies were predominantly female. Therefore, the applicability of the findings to male individuals with BPD is limited, as BPD manifests differently according to gender. For example, men tend to respond to negative affect more explosively, aggressively or impulsively, whereas women respond with greater levels of self-focus.

Unfortunately, we were not able to identify any two or more RCTs evaluating the same comorbidity-specific treatment. Although adaptations of BPD therapies for defined comorbidities are now available and have been tested in single RCTs, e.g. for DBT (DBT-adapted for post-traumatic stress disorder, DBT prolonged exposure) and MBT (MBT adapted for eating disorders), MBT adapted for co-occurring substance use disorder, replication studies are presently lacking.

Furthermore, we were unable to identify any two or more RCTs testing the prominent therapies of transference-focused therapy (TFP) and schema-focused therapy (SFT) in their standard formats against unspecific controls. There was only one RCT testing TFP against an unspecific control treatment, and SFT was only tested head-to-head against alternative treatments or conducted in a non-standard group format. However, RCTs testing standard SFT against DBT and MBT delivered in a non-standard format against an unspecific control are under way.

Control treatments varied across the studies. However, sensitivity analyses of the 2020 Cochrane review revealed no substantial difference in effect estimates observed by comparisons with TAU or waiting list/no treatment, supporting the joint analysis of corresponding effect estimates in the same analysis. It seems that comparisons with TAU in older studies (where typical care for individuals with BPD was certainly poorer than today) or in countries where TAU is of lower quality might be associated with larger effect estimates, whereas more recent comparisons of the same treatments and outcomes or studies in higher-income countries result in smaller effects. However, a recent meta-analysis found evidence that participants allocated to TAU in general tend to improve to a limited extent, with possible reasons being the disclosure of the diagnosis, involvement of a concerned healthcare professional and time effects. This finding points to the need for conducting RCTs to find out the very treatment effects beyond these general factors.

In terms of outcomes, it is evident that there still is no consensus about a core battery of outcomes and measures to be used in BPD treatment evaluation studies. Although specific treatments build on different aetiology models and postulate different core problems, they tend to prioritise and assess different outcomes. For instance, MBT considers a lack of the ability to mentalise, i.e. to identify mental states (such as beliefs, wishes, feelings, thoughts, etc.) in oneself and others, as the BPD core problem, which leads to interpersonal difficulties. DBT, however, considers a disturbed emotion regulation as the core problem, which leads to self-harming and suicidal behaviour. Therefore, MBT studies usually report on interpersonal problems, but not impulsive or affective-dysregulative outcomes, whereas the opposite is the case for DBT. However, it would be helpful to know how different therapies perform on a common set of BPD-specific outcomes, to identify their respective profiles of action. Fortunately, efforts have been made recently by an international consortium of researchers to identify a core standard battery of outcomes for individuals with personality disorders. To date, BPD-specific measures are available that allow for a very detailed assessment of individual BPD symptoms, like the Zan-BPD. Clinical Global Impression Scale adapted for BPD (CGI-BPD) or BPDSI-IV. Until recently, several BPD-specific outcomes that are specifically important for individuals affected are still neglected across all studies, like avoidance of abandonment, chronic feelings of emptiness or identity disturbance. Moreover, longitudinal findings point to the relevance of psychosocial outcomes, as many individuals affected by BPD experience impaired social and vocational functioning over sustained periods of time, even after BPD-specific symptoms have diminished and the full diagnostic criteria are no longer met.

However, the evidence of long-term outcomes of psychotherapies in BPD is still scarce. More studies would be required to accurately evaluate these treatments.

Quality of the evidence

Across all included studies, incomplete outcome reporting (attrition bias) and other bias in terms of affiliations of the study authors to the treatment under test, or different amounts of attention spent to the treatment groups, were the most common reasons for a high risk-of-bias rating (34.4 and 56.3%). The quality of the overall evidence was rated very low for the majority of comparisons and outcomes, although there was also moderate-quality evidence available for some outcomes of DBT-ST, and low-quality evidence for DBT, MBT, ERG, MACT and STAPP. The most limiting factor was imprecision of results because of the restriction to limited observations (single study effects only, small sample sizes) or risk of bias for the above-mentioned reasons in the primary studies. We observed a clear tendency of larger effect sizes in smaller samples, which may be a result of methodological issues in smaller samples or bias owing to non-publication of unfavourable results.

Potential biases in the review process

Since we applied a maximally sensitive and comprehensive search strategy, including searches in a large number of bibliographic databases and study registers, tracing of reference lists and contacting study authors if relevant information was missing, and as we did not apply any language, publication format or publication date restrictions, we are confident that we have identified all relevant eligible evidence. As both data extractions and risk-of-bias ratings were doubly assessed by two reviewers independently, and disagreements resolved, we did our best to avoid any bias during the review process.

Agreements and disagreements with other systematic reviews and meta-analyses

Cristea et al provided a systematic review and meta-analysis of psychotherapies for BPD, covering relevant studies published until November 2015. Not surprisingly, the evidence has

https://doi.org/10.1192/bjp.2021.204 Published online by Cambridge University Press
accumulated since this time, so this paper included a substantially higher number of studies that were not available at the time that review was prepared. For DBT, Cristea et al report an effect estimate of Hedge’s $g = 0.34$ (95% CI 0.15–0.53) on BPD-relevant measures, which parallels the findings of this paper for the effect of standard DBT on self-harm (SMD −0.32, 95% CI −0.92 to −0.16). As substantially broader categories of interventions were applied by Cristea et al (i.e. treatments grouped into DBT, psychodynamic approaches, CBT or other interventions), and so the remaining findings cannot be compared with the results of this paper.

Oud et al published another systematic review and meta-analysis of specialised psychotherapies for adults with BPD, which covers the evidence up to November 2017. In contrast to our review, eligible interventions were restricted to DBT, MBT, SFT and TFP. As for the review of Cristea et al, new evidence has become available that had not been included in the Oud et al review (four studies on DBT, 106–108,66,67 one study on MBT41). Nonetheless, the findings of Oud et al and this review do not differ substantially for those interventions that had been subject to both reviews. Also, the rating of the quality of the evidence as low or very low for the main part of findings still applies.

In conclusion, the findings of this review support the use of psychotherapy in BPD. Although the overall quality of the evidence is low to very low for most interventions, the evidence on drug treatments is neither more robust in the main part, nor does it suggest any substantial treatment effects for any single drug. One of the major findings of this review is the evidence of promising effects of add-on group interventions, especially DBT-ST, ERG, MACT and STEPPS. Although this review does not allow for the assessment of the relative efficacy of individual versus group treatments, the results support the notion that add-on group interventions should be provided to individuals with BPD who already undergo treatment, if group treatments are not yet part of the therapy provided. As a recent meta-analysis found evidence of limited improvements in control treatments, it may be reasonable to supplement non-specialised treatment by BPD-specific group interventions, as long as no specialist individual treatment is available. However, individuals with BPD must not be detained from coherent, comprehensive treatments, as the encouraging effects of add-on interventions have only been observed in the context of ongoing treatments. Moreover, the long-term effects of add-on treatments are uncertain.

More replication studies are needed to increase the certainty of the evidence, and they should preferably be conducted by independent research groups not affiliated with any treatment in this field. More research is also needed for interventions that have been developed to meet the needs of individuals with BPD and defined BPD criteria as defined by DSM, which can be done by the use of the Zan-BPD, BPSDI-IV or CGI-BPD, for example. To reflect the reality of individuals affected by BPD, the observation periods should be extended so long-term effects could be followed up. This is true both for standalone and add-on treatments, the sustainability of which still needs to be established. Also, a consensus regarding adequate control treatments could help to understand the true effects of experimental treatments. Control groups need to be designed and sufficiently described to allow for ascribing observed between-group effects to individual experimentally manipulated factors, be it the use or non-use of a coherent treatment protocol, or the use of a specific treatment approach. In an ideal world, not only would participants be randomly allocated to treatment and control groups, but also intervenors, or intervenor teams to treatments. Finally, although we can be sure that psychotherapy in general is helpful for individuals with BPD, more research is needed to understand who benefits most from which kind of treatment. A project aiming to investigate this question using an individual patient data meta-analysis is under way.

Jutta M. Stoffers-Winterling, Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany; Ole Jakob Storeba, Mental Health Services, Region Zealand Psychiatry, Denmark; and Department of Psychology, University of Southern Denmark, Denmark; Michael T. Kongerlund, Mental Health Services, Region Zealand Psychiatry, Denmark; and Department of Psychology, University of Southern Denmark, Denmark; Eiel Faltinsen, Mental Health Services, Region Zealand Psychiatry, Denmark; Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Denmark; and Cochran Denmark, Department of Clinical Research, University of Southern Denmark, Denmark; Adam Todorovac, Mental Health Services, Region Zealand Psychiatry, Denmark; Mie Sedoc Jørgensen, Mental Health Services, Region Zealand Psychiatry, Denmark; Christian P. Sales, Research & Innovation Department, Nottinghamshire Healthcare NHS Foundation Trust, UK; Henriette Edemann Callesen, Mental Health Services, Region Zealand Psychiatry, Denmark; Johanne Pereira Ribeiro, Mental Health Services, Region Zealand Psychiatry, Denmark; Birgit A. Völl, Department of Forensic Psychiatry, Rostock University Medical Centre, Germany; Klaus Lieb, Department of Psychiatry and Psychotherapy, University Medical Center Mainz, Germany; Erik Simonsen, Mental Health Services, Region Zealand Psychiatry, Denmark; and Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

Correspondence: Jutta M. Stoffers-Winterling. Email: j.stoffers-winterling@uni-mainz.de.

First received 23 Apr 2021, final revision 5 Nov 2021, accepted 23 Nov 2021

Supplementary material

To view supplementary material for this article, please visit http://doi.org/10.1192/bjp.2021.204.

Data availability

The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.

Acknowledgements

We thank Trine Lacoopid Kæstel for conducting the bibliographic literature searches.

Author contributions

J.M.S.-W. and O.J.S. designed and conceived the study, and drafted the manuscript. J.M.S.-W. was responsible for statistical analysis. All authors revised the manuscript. All authors have agreed on the final manuscript and the decision to submit it for publication.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Declaration of interest

J.M.S.-W. is a board-certified psychotherapist (CBT) and received training in DBT. She has no financial conflicts of interest to declare. O.J.S. is trained in psychoanalytic group analysis and psychoanalytic child and adolescent individual psychotherapy and was involved in a trial of MBT for adolescents with BPD. He has no financial conflicts of interests to declare. E.K. is a certified MBT therapist and supervisor. He receives money from conducting MBT training. M.S.-J is trained in DBT and psychodynamic therapy and was involved in a trial on MBT for adolescents with BPD. He has no financial conflicts of interests to declare. E.S. is trained in psychoanalytic group analysis. K.L. is a cognitive-behavioural psychotherapist with a special interest in schema therapy. E.F., A.T., C.P.S., H.E.C., J.P.R. and B.A.V. have no conflicts of interest to declare.

https://doi.org/10.1192/bjp.2021.204 Published online by Cambridge University Press
References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-III. American Psychiatric Association, 1980.
2. Simonson S, Bateman A, Bothus M, Dalewijk HJ, Doering S, Kaera A, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregulation 2019; 6: 9.
3. Hutsebaut I, Willemsen E, Bachrach N, Van R. Improving access to and effectiveness of mental health care for personality disorders: the guideline-informed treatment for personality disorders (GIT-PD) initiative in the Netherlands. Borderline Personal Disord Emot Dysregulation 2020; 7: 16.
4. National Health and Medical Research Council (NHMRC). Clinical Practice Guideline for the Management of Borderline Personality Disorder. NHMRC, 2012 (https://www.nhmrc.gov.au/about-us/publications/clinical-practice-guideline-borderline-personality-disorder#block-views-block-file-attachment-content-block-1).
5. National Institute for Health and Care Excellence (NICE). 2018 Surveillance of Personality Disorders (NICE Guidelines CG77 and CG78). NICE, 2018 (https://www.nice.org.uk/guidance/cg73/resources/2018-surveillance-of-personality-disorders-nice-guidelines-cg77-and-cg78-6940690500/chapter/1-surveillance-decision-tab-evidence).
6. Stoffers-Winterling J, Vollm B, Lieb K. Is pharmacotherapy useful for treating personality disorders? Expert Opin Pharmacother 2021; 22(4): 393–5.
7. Stoffers-Winterling J, Storebo OJ, Lieb K. Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep 2020; 22: 31.
8. Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongslev MT, Mattivi JT, Jørgensen MS, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2020; 5: CD012955.
9. Stoffers JM, Vollm BA, Rucker G, Timmer A, Huband N, Lieb K. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2012; 5: CD005652.
10. Higgins JPT, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions (2nd edn). Wiley-Blackwell, 2020.
11. Storebo OJ, Stoffers-Winterling JM, Vollm BA, Kongslev MT, Mattivi JT, Kielsholm ML, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 2020; 5: CD012955.
12. Storebo OJ, Stoffers-Winterling JM, Vollm B, Kongslev M, Mattivi J, Kielsholm ML, et al. Psychological therapies for People with Borderline Personality Disorder [Cochrane Protocol]. PROSPERO, 2018 (https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018091043).
13. Wong J, Bahlji A, Khalid-Khan S. Psychotherapies for adolescents with subclinical and borderline personality disorder: a systematic review and meta-analysis. Can J Psychiatry Can Psychiatr 2020; 65: 5–15.
14. Jørgensen MS, Storebo OJ, Stoffers-Winterling JM, Faltinsen E, Todorovac A, Simonsen E. Psychological therapies for adolescents with borderline personality disorder (BPD) or BPD features—a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. PLoS One 2021; 16: e0245351.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition, Revised. American Psychiatric Association, 1987.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Association, 1994.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision. American Psychiatric Association, 2000.
18. American Psychiatric Association, American Psychiatric Association, DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. American Psychiatric Association, 2013.
19. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (10th revision, 2nd edn). World Health Organization, 2004.
20. Higgins JPT, Altmann DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
21. The Cochrane Collaboration. Review Manager (RevMan) [Computer Program] Version 5.4. The Cochrane Collaboration, 2020 (https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download/download-and-installation).
22. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.
23. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration, 2011 (www.cochrane-handbook.com).
24. Guyatt G, Oxman AD, Akhtar EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383–94.
25. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-behavioural treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991; 48: 1060–4.
26. Linehan MM, Tutek DA, Heard HL, Armstrong HE. Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 1994; 151: 1771–6.
27. Bateman A, Fonagy P. Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 1999; 156: 1563–9.
28. Carter G, Wilcox C, Lewin T, Conrad A, Bendt N. Hunter DBT project: randomized controlled trial of dialectical behaviour therapy in women with borderline personality disorder. Aust N Z J Psychiatry 2010; 44: 162–73.
29. Koons CR, Robins CJ, Tweed J, Lynch TR, Gonzalez AM, Morse JQ, et al. Efficacy of dialectical behaviour therapy in women veterans with borderline personality disorder. Behav Ther 2001; 32: 371–90.
30. Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallo RJ, Heard HL, et al. Two year randomized controlled trial and follow-up of dialectical behaviour therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006; 63: 757–66.
31. Mohamadzadeh L, Makvandi B, Pasha R, Bakhtiarpour S, Haleef S. Comparing of the effect of dialectical behaviour therapy (DBT) and schema therapy (ST) on reducing mood activity and suicidal thoughts in patients with borderline personality disorder. Acta Medica Mediterr 2017; 2012: 1025–31.
32. van den Bosch LMC, Verheul R, Schippers GM, van den Brink W. Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behav Res Th 2005; 43: 1231–41.
33. Gratz KL, Gunderson JG. Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behav Ther 2006; 37: 25–35.
34. Gratz KL, Tull MT, Levy R. Randomized controlled trial and uncontrolled 9-month follow-up of an adjunctive emotion regulation group therapy for deliberate self-harm among women with borderline personality disorder. Psychol Med 2014; 44: 2099–112.
35. Weinberg J, Gunderson JG, Henneman J, Cutter CJ Jr. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. J Personal Disord 2006; 20: 482–92.
36. Zanarini MC, Frankenburg FR. A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. J Personal Disord 2008; 22: 284–90.
37. Zanarini MC, Conley LC, Temes CM, Fitzmaurice GM. Randomized controlled trial of web-based psychoeducation for women with borderline personality disorder. J Clin Psychiatry 2018; 79: 52–9.
38. Bianchi V, Cofri N, Corto M, Lagrotteria B, Mardi M, Navari S, et al. Dialectical behaviour therapy (DBT) for forensic psychiatric patients: an Italian pilot study. Crim Behav Ment Health 2019; 29: 122–30.
39. Kredlow MA, Szuhany KL, Lo X, Sei H, Gottlieb JD, Rosenberg SD, et al. Cognitive behavioral therapy for posttraumatic stress disorder in individuals with severe mental illness and borderline personality disorder. Psychiatry Res 2017; 249: 86–93.
40. Gregory RJ, Chlebowski S, Kang D, Remen AL, Soderberg MG, Stepkovich I, et al. A controlled trial of psychodynamic psychotherapy for co-occurring borderline personality disorder and alcohol use disorder. Psychother Theory Res Prac Train 2008; 45: 28–41.
41. Lauermann EMP, Luyten P, Kikkert MJ, Westra D, Peen J, Molenberghs G, et al. Hospital mentalization-based treatment v. specialist treatment as usual in patients with borderline personality disorder: randomized controlled trial. Psychiatr Med 2018; 48(15): 2522–9.
42. Linehan MM. Skills Training Manual for Treating Borderline Personality Disorder (1st edn). The Guilford Press, 1993.
43. Linehan MM. Cognitive-Behavioral Treatment of Borderline Personality Disorder (1st edn). The Guilford Press, 1993.
44. Bateman A, Fonagy P. Psychotherapy for Borderline Personality Disorder: Mentalization-Based Treatment. Oxford University Press, 2004.
45. Klemann GL, Weissman M, Rounsaville BJ, Chevlin ES. Interpersonal Psychotherapy of Depression. Basic Books, 1984.
46. Markowitz JC, Skodol AE, Bleiberg K. Interpersonal psychotherapy adapted for borderline personality disorder (PT-BPD): a review of available data and a proposal of revision. J Psychol Psychother 2015; 5: 229.
Suicidal thoughts and planning in the Book of Tobit

George Stein

The Book of Tobit is a short but charming Jewish novella found in the Apocrypha. It concerns the family life of Tobit and his relatives, who live in the Persian diaspora, and was written in Aramaic probably between 200 and 300 BCE but comes to us through its Greek translation. Tobit is blinded when some pigeon droppings fall into his eyes and this causes his depression. Sarah is distressed because all seven times she gets married her bridegrooms die on their wedding night, leaving the marriages unconsummated, and this is all the work of the wicked Persian demon Asmodeus. As a consequence, both Tobit and Sarah suffer from depression and suicidal thoughts. The Book of Tobit is non-canonical in both the Jewish and Protestant religions, but is canonical for Catholics. Tobot 3: 1–11 and 16 is read in Catholic churches in the two-year cycle on the Wednesday of the ninth week of year one, and the following verses give a good description of their depression and suicidal thoughts.

Tobit’s depression and suicidal thoughts:

1 Then with much grief and anguish of heart I wept, and with groaning began to pray: ‘May the Lord hear my sighing and listen to my prayer…’

Sarah’s suicidal thoughts:

10 On that day she was grieved in spirit, and wept. When she had gone up to her father’s upper room she intended to hang herself. But she thought over and said: ‘Never shall I reproach my father, saying to him: “You had only one beloved daughter but she hanged herself because of her distress”. And I shall bring my father in his old age down in sorrow to Hades. It is better for me not to hang myself, but to pray to the Lord that I may die and not listen to these reproaches anymore.’

These short extracts give us a clinically authentic description of suicidal thoughts at around 300 BCE that resemble those spoken by patients today. Thus, suicidal thoughts tend to be repetitive and the prayers of both Tobit and Sarah, which ask God to take their lives, are repeated several times. An indication of the severity of suicidal thoughts is whether there is any indication of planning or method. Sarah reports her intention to hang herself in her father’s upper room, which gives a clear description of intent, method and planning. Sarah does not do it, but what holds her back is the thought of the distress it will cause a close relative, in her case, her father. Today most patients with strong suicidal thoughts are also commonly restrained by thoughts of their relatives, often their children. This Book of Tobit has six main characters, five of whom have either depression or anxiety and depression; a more detailed account is given in my book The Hidden Psychiatry of the Old Testament.

© The Author(s), 2022. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists